Please login to the form below
Eloctate
This page shows the latest Eloctate news and features for those working in and with pharma, biotech and healthcare.
Dupixent drives Sanofi again, but other new drugs are lagging
There was bad news for Genzyme’s blood disorders unit, however. Long-acting haemophilia A drug Eloctate – acquired as part of Sanofi’s $11.9bn acquisition of Bioverativ last year – succumbed ... Sanofi took a hefty 1.8bn charge on its books in
Latest news
-
EMA clears Novo Nordisk’s long-acting haemophilia A drug
Takeda’s Shire unit already has a long-acting factor VIII product on the market in Adynovate, as does Sanofi with Eloctate from its recent Bioverativ acquisition, Bayer with Kovaltry, and
-
Sanofi exits R&D pact with Alnylam on rare disease
Haemophilia and other rare blood diseases have become key therapeutic targets for Sanofi in the wake of its acquisition of Bioverativ – which gave it long-acting clotting factor therapies Eloctate and
-
Sanofi extends growth spurt thanks to Genzyme, Dupixent
While growth for haemophilia treatments Eloctate and Alprolix – acquired as part of Sanofi’s $11.9bn acquisition of Bioverativ last year – remained fairly sluggish, the quarter was marked first sales contribution ... Eloctate and Alprolix grew 4%
-
Roche gets wider approval for haemophilia drug Hemlibra
Adynovate, Biogen’s Eloctate, Bayer’s Kovaltry and CSL Behring’s Afstyla – with the advantage of being dosed every one, two, or four weeks depending on need, rather than multiple times
-
Bayer roll-out of haemophilia drug Jivi gathers pace
and Eloctate, and CSL Behring’s Afstyla, uptake hasn’t been as quick as many had hoped, so Jivi is entering a challenging market.
More from news
Approximately 3 fully matching, plus 26 partially matching documents found.
Latest Intelligence
-
Deal Watch January 2018
s closing price on 19 January), Sanofi gains the marketed products, Eloctate (haemophilia A therapy) and Alprolix (haemophilia B therapy), as well as a pipeline of candidates focused on rare blood ... disorders. During 2016 Eloctate and Alprolix
More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
- Regeneron says antibody for COVID-19 could be ready this year
- EMA clears BMS’ oral multiple sclerosis drug Zeposia
- Amgen adds Otezla to the COVID-19 candidate list
- Guiding star of science leads AstraZeneca to breakthrough in child tumour therapy
- New data backs remdesivir for COVID-19, but rings hydroxychloroquine alarm bell
- Alnylam and Vir plan gene-silencing attack on COVID-19 virus
- ASCO: Momentum gathers behind next wave of CAR-T therapies
- Lilly starts world first trial of an antibody drug for COVID-19
- Pfizer’s Ibrance misses the mark in early breast cancer
- Rise of the patient influencer
- Working together against COVID-19
- Vicky Bramham, Managing Director at OPEN Health PR shares tips on media relations during COVID-19
PMHub
HAVAS Just::
HAVAS Just:: is a different kind of healthcare communications agency. Our mission is to create campaigns that make people think....
Latest intelligence
- Working together against COVID-19
- Analysing social media conversations to see what HCPs are saying online about the global pandemic...
- Vicky Bramham, Managing Director at OPEN Health PR shares tips on media relations during COVID-19
- Vicky speaks with freelance health journalist Jacqui Thornton who gives her expert view on how best to approach media relations during this unprecedented time....
- Are biobetters a market access opportunity?
- Biobetters are biologics that have been improved compared to the marketed originator, for example in efficacy, safety, tolerability or dosing regimen....
Quick links
Infographics
